Thorough cardiac QTc interval conductance assessment of a novel oral tranexamic acid treatment for heavy menstrual bleeding

Bibliography

• Shah RR. Drug-induced prolongation of the QT interval: regulatory dilemmas and implications for approval and labeling of a new chemical entity. Fundam Clin Pharmacol 2002;16:147-56
   PubMed Web of Science ®Google Scholar
• Fenichel RR, Malik M, Antzelevitch C, Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013-22
   PubMedGoogle Scholar
• Pratt CM, Hertz RP, Ellis BE, Risk of developing life-threatening ventricular arrhythmia associated with tefenadine in comparison with over-the-counter antihistamines, ibuprofen and clemastine. Am J Cardiol 1994;73:346-52
   PubMed Web of Science ®Google Scholar
• Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med 2004;350:1013-22
   PubMed Web of Science ®Google Scholar
• Shah RR. Drugs, QT interval prolongation and ICH E14: the need to get it right. Drug Saf 2005;28:115-25
   PubMed Web of Science ®Google Scholar
• Yang T, Snyders D, Roden DM. Drug block of I(Kr): model systems and relevance to human arrhythmias. J Cardiovasc Pharmacol 2001;38:737-44
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration/Health Canada. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs: Preliminary concept paper, 15 November 2002
   Google Scholar
• International Conference on Harmonisation (ICH); Safety pharmacology studies for assessing the potential for delayed ventricular repolarization (QT interval prolongation) by human pharmaceuticals. International Conference on Harmonisation (ICH) of Technical Requirements for Registration of Pharmaceuticals for Human Use, 7 February 2002
   Google Scholar
• United States Food and Drug Administration, HHS. International Conference on Harmonisation; Guidance on E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Fed Regist 2005;70:61134-5
   PubMedGoogle Scholar
• Pilbrant A, Schannong M, Vessman J. Pharmacokinetics and bioavailability of tranexamic acid. Eur J Clin Pharmacol 1981;20:65-72
   PubMed Web of Science ®Google Scholar
• Wellington K, Wagstaff AJ. Tranexamic acid: a review of its use in the management of menorrhagia. Drugs 2003;63:1417-33
   PubMed Web of Science ®Google Scholar
• Pfizer Canada. Cyklokapron (tranexamic acid) package insert. Kirkland, Quebec; 2003
   Google Scholar
• Mannucci PM. Drug therapy: hemostatic drugs. N Engl J Med 2003;339:245-53
   Google Scholar
• Gleeson NC, Buggy F, Sheppard BL, Bonnar J. The effect of tranexamic acid on measured menstrual loss and endometrial fibrinolytic enzymes in dysfunctional uterine bleeding. Acta Obstet Gynecol Scand 1994;73:274-7
   PubMed Web of Science ®Google Scholar
• Preston JT, Cameron IT, Adams EJ, Comparative study of tranexamic acid and norethisterone in the treatment of ovulatory menorrhagia. Br J Obstet Gynaecol 1995;102:401-6
   PubMedGoogle Scholar
• Morganroth J, Ilson BE, Shaddinger BC. Evaluation of vardenafil and sildenafil on cardiac repoloriazation. Am J Cardiol 2004;93:1378-83
   PubMed Web of Science ®Google Scholar
• Bloomfield DM, Kost JT, Ghosh K, The effect of moxifloxacin on QTc and implications for the design of thorough QT studies. Clin Pharm Ther 2008;84:475-80
   PubMed Web of Science ®Google Scholar
• Wysowski DK, Corken A, Gallo-Torres H, Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions. Am J Gastroenterol 2001;96:1698-703
   PubMed Web of Science ®Google Scholar
• Morganroth J. A definite or thorough phase 1 QT ECG trial as a requirement for drug safety assessment. J Electrocardiol 2004;37:25-9
   PubMed Web of Science ®Google Scholar
• United States Food and Drug Administration, HHS. International Conference on Harmonisation; Guidance on E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs: Questions and answers, November 2008
   Google Scholar
• Warmke JW, Ganetzky B. A family of potassium channel genes related to EAG in Drosophila and mammals. Proc Natl Acad Sci USA 1994;91:3438-42
   PubMed Web of Science ®Google Scholar
• Extramiana F, Maison-Blanche P, Badilini F, Circadian modulation of QT rate dependence in healthy volunteers: gender and age differences. J Electrocardiol 1999;32:33-43
   PubMed Web of Science ®Google Scholar
• Toivonen L. More light of QT interval measurement. Heart 2002;87:193-4
   PubMed Web of Science ®Google Scholar
• Ahnve S, Vallin H. Influence of heart rate and inhibition of autonomic tone on the QT interval. Circulation 1982;65:435-9
   PubMed Web of Science ®Google Scholar
• Extramiana F, Maison-Blanche P, Cabanis MJ, Clinical assessment of drug-induced QT prolongation in association with heart rate changes. Clin Pharmacol Ther 2005;77:247-58
   PubMed Web of Science ®Google Scholar
• Chen X, Cass JD, Bradley JA, QT prolongation and proarrhythmia by moxifloxacin: concordance of preclinical models in relation to clinical outcome. Br J Pharmacol 2005;146:792-9
   PubMed Web of Science ®Google Scholar
• Hnatkova K, Malik M. Optimum formulae for heart rate correction of the QT interval. Pacing Clin Electrophysiol 1999;22:1683-7
   PubMed Web of Science ®Google Scholar
• Shah RR. The significance of QT interval in drug development. Br J Clin Pharmacol 2002;54:188-202
   PubMed Web of Science ®Google Scholar